Literature DB >> 26985143

Cost-effectiveness analysis of whole-mount pathology processing for patients with early breast cancer undergoing breast conservation.

N J Look Hong1, G M Clarke2, M J Yaffe2, C M B Holloway1.   

Abstract

BACKGROUND: Obtaining accurate histopathologic detail for breast lumpectomy specimens is challenging because of sampling and loss of three-dimensional conformational features with conventional processing. The whole-mount (wm) technique is a novel method of serial pathologic sectioning designed to optimize cross-sectional visualization of resected specimens and determination of margin status.
METHODS: Using a Markov chain cohort simulation cost-effectiveness model, we compared conventional processing with wm technique for breast lumpectomies. Cost-effectiveness was evaluated from the perspective of the Canadian health care system and compared using incremental cost-effectiveness ratios (icers) for cost per quality-adjusted life-year (qaly) over a 10-year time horizon. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the model with willingness-to-pay (wtp) thresholds of $0-$100,000. Costs are reported in adjusted 2014 Canadian dollars, discounted at a rate of 3%.
RESULTS: Compared with conventional processing, wm processing is more costly ($19,989 vs. $18,427) but generates 0.03 more qalys over 10 years. The icer is $45,414, indicating that this additional amount is required for each additional qaly obtained. The model was robust to all variance in parameters, with the prevalence of positive margins accounting for most of the model's variability.
CONCLUSIONS: After a wtp threshold of $45,414, wm processing becomes cost-effective and ultimately generates fewer recurrences and marginally more qalys over time. Excellent baseline outcomes for the current treatment of breast cancer mean that incremental differences in survival are small. However, the overall benefit of the wm technique should be considered in the context of achieving improved accuracy and not just enhancements in clinical effectiveness.

Entities:  

Keywords:  Breast cancer; cost-effectiveness; pathology

Year:  2016        PMID: 26985143      PMCID: PMC4780586          DOI: 10.3747/co.23.2917

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  38 in total

1.  Diagnostic discrepancies in breast specimens subjected to gross reexamination.

Authors:  E L Wiley; P Keh
Journal:  Am J Surg Pathol       Date:  1999-08       Impact factor: 6.394

2.  Representing uncertainty: the role of cost-effectiveness acceptability curves.

Authors:  E Fenwick; K Claxton; M Sculpher
Journal:  Health Econ       Date:  2001-12       Impact factor: 3.046

Review 3.  Health outcomes in economic evaluation: the QALY and utilities.

Authors:  Sarah J Whitehead; Shehzad Ali
Journal:  Br Med Bull       Date:  2010-10-29       Impact factor: 4.291

4.  Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.

Authors:  Lindsay Hedden; Susan O'Reilly; Caroline Lohrisch; Stephen Chia; Caroline Speers; Laurel Kovacic; Suzanne Taylor; Stuart Peacock
Journal:  Oncologist       Date:  2012-02-02

5.  Variability in reexcision following breast conservation surgery.

Authors:  Laurence E McCahill; Richard M Single; Erin J Aiello Bowles; Heather S Feigelson; Ted A James; Tom Barney; Jessica M Engel; Adedayo A Onitilo
Journal:  JAMA       Date:  2012-02-01       Impact factor: 56.272

Review 6.  Breast-conserving treatment of breast cancer--oncological and reconstructive aspects.

Authors:  Stefan Kramer; Maren Darsow; Sherko Kummel; Rainer Kimmig; Mahdi Rezai
Journal:  Gynakol Geburtshilfliche Rundsch       Date:  2008-04-16

7.  Spatial resolution requirements for acquisition of the virtual screening slide for digital whole-specimen breast histopathology.

Authors:  Gina M Clarke; Judit T Zubovits; Marko Katic; Chris Peressotti; Martin J Yaffe
Journal:  Hum Pathol       Date:  2007-08-17       Impact factor: 3.466

Review 8.  Willingness to pay for cancer prevention.

Authors:  Timothy L Hunt; Bryan R Luce; Matthew J Page; Robin Pokrzywinski
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.

Authors:  Lisa K Dunnwald; Mary Anne Rossing; Christopher I Li
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial.

Authors:  Anthony B Miller; Claus Wall; Cornelia J Baines; Ping Sun; Teresa To; Steven A Narod
Journal:  BMJ       Date:  2014-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.